Venlo, The Netherlands, Jan. 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter and full year 2023.

Press release date/time: Tuesday, February 6, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.

Conference call date/time: Wednesday, February 7, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.

Three options for joining the conference call

Register for call back connection - Click here: Connect me

Service is available 15 minutes before the call starts

Dial-in by phone

U.S.: +1 646 828 8193

UK: +44 (0)330 165 3655

GER: +49 (0)69 6610 2492

Conference ID: 2206067

To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.

Access the audio webcast - Click here: Access Webcast

A conference call replay will be available by using the following link:

https://event.webcasts.com/starthere.jsp?ei=1643464&tp_key=a2e231b651

Contact: IR@qiagen.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to

Insight solutions that enable customers to gain valuable molecular insights from samples containing

the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from

blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for

analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable

insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN

provides solutions to more than 500,000 customers around the world in Molecular Diagnostics

(human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics).

As of September 30, 2023, QIAGEN employed more than 6,000 people in over 35 locations worldwide.

Further information can be found at http://www.qiagen.com.

source: QIAGEN N.V.

category: Financial

John Gilardi
QIAGEN GmbH
+49 2103 29 11711
IR@qiagen.com

Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
IR@qiagen.com

Alexandra König
QIAGEN N.V.
+49 2103 29 11709
IR@qiagen.com

QIAGEN N.V. to release results for Q4 2023 and hold webcast